Antiarrhythmic drugs remain a mainstay for managing symptomatic atrial fibrillation despite limitations like proarrhythmic and noncardiovascular toxicities.
A ntiarrhythmic medications have been available for nearly 100 years and remain a mainstay in the management of atrial fibrillation (AF).Goals of therapy with the use of these drugs include a reduction in the frequency and duration of episodes of arrhythmia as well an emerging goal of reducing mortality and hospitalizations associated with AF.The use of these drugs has been limited by both proarrhythmic and noncardiovascular toxicities as well as often modest antiarrhythmic efficacy.Despite these limitations, antiarrhythmic drugs remain widely prescribed for the management of symptomatic AF, and a host of new antiarrhythmic drugs are in various stages of clinical development.This review will focus primarily on antiarrhythmic drug use in patients with AF in the absence of significant structural heart disease or congestive heart failure.
Peter Zimetbaum (2012) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: